Intervet/Schering-Plough has announced that the license for Leptavoid-H has been improved allowing concurrent use with Bovilis BVD.

Intervet/Schering Plough says that given both vaccines are typically administered in the busy pre-turnout period, this will ease on-farm workload and should help to ensure that all primary courses or boosters take place sufficiently in advance of the period of risk.

Each vaccine is to be given by separate routes and sites, to animals of 8 months or older. The concurrent use in cattle may result in fewer animal interventions, less stress and better welfare.

The studies, undertaken by Intervet/Schering Plough's R&D division in the UK, focussed on both the safety and efficacy aspects of the concurrent administration of Leptavoid-H with Bovilis BVD. The company says no systemic adverse events occurred, there was no effect on the outcome of pregnancy or milk yields and the efficacy in cattle was not compromised.

Leptavoid-H is licensed to reduce the shedding of Leptospira interrogans serovar hardjo in urine. Leptavoid-H is the only Leptospirosis vaccine licensed to improve herd fertility when Leptospira hardjo is the cause of herd infertility, and the only vaccine proven to protect stock against both strains in the UK.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.